Test whether under GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis, Selank still retains anxiolytic / adaptive-behavior phenotype
Selank (tuftsin analogue Thr-Lys-Pro-Arg-Pro-Gly-Pro) is framed through GABAergic gene expression and benzodiazepine-comparable anxiolysis, yet GABA-class attribution is often assumed to explain its adaptive-behavior phenotype. This discussion asks whether residual Selank anxiolytic or adaptive-behavior under a GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis still requires a path beyond GABA-class attribution.
Claim
On a matched stressor ± Selank (tuftsin analogue Thr-Lys-Pro-Arg-Pro-Gly-Pro) ± GABA-A / benzodiazepine-matched condition (e.g. bicuculline GABA-A antagonist, flumazenil BDZ antagonist, or BDZ-occupancy match) titrated so the match abolishes GABA-class anxiolysis, plus anxiolytic / adaptive-behavior endpoint: under that GABA-A / BDZ-match condition, residual Selank anxiolytic / adaptive-behavior remains ≥50% of the Selank without-GABA-A/BDZ-match arm on the same panel (named comparator = Selank without-GABA-A/BDZ-match arm under matched stressor) — assumption-kill / gaba-insufficiency.
Why it matters
Filatova maps Selank/GABA GABAergic gene expression in IMR-32; Volkova shows Selank GABAergic gene expression in rat frontal cortex; Kozlovskaya maps Selank tuftsin-family adaptive behavior under stress; Medvedeva shows Selank×diazepam synergy under UCMS. P21 asks whether residual Selank anxiolytic / adaptive-behavior under a GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis still requires a path beyond GABA-class attribution — gaba-insufficiency assumption-kill. Distinct from P15 (BPC residual-FBXO22), P16 (LKKTETQ-Cc), P17 (MOTS-c/folate), P18 (SS-31/ROS-scavenger), P19 (ARA290/IRR), and P20 (Semax/TrkB; Selank≠Semax; GABA≠TrkB); NOT FOXO4×LOF; NOT N18 theanine/adenosine; skip-list unused; orthosteric_drift=false. Soft-claims: discussion — matched residual-under-GABA-match H2H UNKNOWN; PRIOR_ART UNKNOWN; soft-complete empty ≠ novelty / ≠ failure; P1–P20 ≠ proof.
Mechanism sketch
gaba-insufficiency assumption-kill: Filatova shows Selank/GABA gene-expression in IMR-32 LITERATURE; Volkova shows Selank GABAergic gene expression in vivo LITERATURE; Kozlovskaya shows Selank tuftsin adaptive-behavior under stress LITERATURE; Medvedeva shows Selank×diazepam UCMS synergy LITERATURE — none score residual Selank under a GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis on the same panel. GABA gene / BDZ-comparable / BDZ-synergy framing is the class PRIOR under kill — PRIOR gene/synergy ≠ matched residual H2H under GABA-A/BDZ-match abolish. P21 scores residual anxiolytic / adaptive-behavior under GABA-A / BDZ match that first abolishes GABA-class anxiolysis, on the same stressor ± Selank ± GABA-A/BDZ-match panel (prefer named published Selank anxiety/adaptive-behavior panel — elevated plus maze / conflict stress — with bicuculline / flumazenil / BDZ-occupancy match; Filatova IMR-32 GABAergic gene panel may support block-QC before new animal/human). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger; NOT P19 ARA290 residual under hematopoietic-matched EPO; NOT P20 Semax residual under TrkB antagonist / BDNF neutralize (Selank ≠ Semax; GABA ≠ TrkB); NOT N18 theanine/adenosine/caffeine. Soft-complete empty ≠ novelty / ≠ failure.
Prior art
- PMID 28293190 / DOI 10.3389/fphar.2017.00089 / PMC5328971 — Filatova: Selank / GABA / olanzapine alter expression of genes involved in GABAergic neurotransmission in IMR-32 cells — GABA-system gene-expression prior; NOT residual-under-GABA-match H2H.
- PMID 26924987 / DOI 10.3389/fphar.2016.00031 / PMC4757669 — Volkova: Selank administration affects expression of genes involved in GABAergic neurotransmission in rat frontal cortex in vivo — GABAergic gene prior; NOT residual under GABA-A/BDZ occupancy match abolish.
- PMID 14969422 / DOI 10.1023/a:1025988519919 — Kozlovskaya: Selank and tuftsin-family short peptides regulate adaptive behavior under conflict/emotional stress — adaptive-behavior prior; NOT residual under GABA-A/BDZ match.
- PMID 28280289 / DOI 10.1155/2017/5091027 / PMC5322660 — Medvedeva: Selank enhances diazepam in reducing anxiety under UCMS (elevated plus maze); combined administration restores anxiety indicators toward pre-stress values — BDZ-class synergy / co-admin prior; NOT residual H2H (no bicuculline/flumazenil abolish arm).
Baseline claimed
Under GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis, Selank still retains anxiolytic / adaptive-behavior phenotype on the same panel — or Filatova/Volkova GABA gene / Kozlovskaya adaptive-behavior / Medvedeva Selank×diazepam synergy / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P19 ARA290/IRR / P20 Semax/TrkB / N18 theanine/adenosine / P1–P20 already settle residual-under-GABA-match.
Baseline measured
Filatova GABA gene IMR-32 LITERATURE (PMID 28293190; phenotype ≠ residual-under-GABA-match H2H). Volkova GABAergic gene in vivo LITERATURE (PMID 26924987; scored without bicuculline/flumazenil/BDZ-occupancy arm that abolishes GABA-class anxiolysis). Kozlovskaya adaptive-behavior/stress LITERATURE (PMID 14969422; adjacent ≠ residual H2H). Medvedeva Selank×diazepam UCMS synergy LITERATURE (PMID 28280289; co-admin synergy ≠ residual H2H under GABA-match abolish). Matched residual Selank anxiolytic / adaptive-behavior under GABA-A / BDZ match that abolishes GABA-class anxiolysis on same panel UNKNOWN (soft-complete Q_resid NON-MATCH / Q_resid_tight=0 / Q_necess NON-MATCH not PARTIAL / Q_necess_b=0 / Q_P20 adjacent NON-MATCH Selank≠Semax GABA≠TrkB / FOXO4∩Selank=0 / BPC∩Selank review NON-MATCH / N18∩Selank chemistry noise NON-MATCH / P15–P19 drift empty/noise). Residual ≥50% of Selank without-GABA-A/BDZ-match arm under GABA-match-abolish condition PREDICTION. P15 ≠ P21; P16 ≠ P21; P17 ≠ P21; P18 ≠ P21; P19 ≠ P21; P20 ≠ P21; N18 ≠ P21; P1–P20 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF. Seed PMID 18661785 lack DOI — demoted out of public prior_art. Reviews 30255741 / 34396551 ≠ experimental anchors.
Actionable limitations
- Do not treat P1–P20 as proving P21 — Filatova/Volkova/Kozlovskaya/Medvedeva GABA gene / adaptive-behavior / BDZ-synergy priors are not a residual-under-GABA-A/BDZ-match H2H; soft-complete empty ≠ demonstrated residual phenotype.
- Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS-scavenger, P19 ARA290/IRR, P20 Semax/TrkB (Selank≠Semax; GABA≠TrkB), or N18 theanine/adenosine; orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or theanine/adenosine/caffeine; NOT FOXO4×LOF (SERIES_FROZEN).
- Filatova/Volkova/Kozlovskaya/Medvedeva lack bicuculline / flumazenil / BDZ-occupancy arm that abolishes GABA-class anxiolysis; incomplete GABA-A/BDZ match / GABA-class anxiolysis not abolished / no residual to score / block-QC failure leave the test inconclusive rather than refuted; no dosing; seed PMID 18661785 lack DOI (honest demote; out of public prior_art); reviews ≠ experimental anchors.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Filatova_Selank_GABA_gene_expression_IMR32 | LITERATURE | Human neuroblastoma IMR-32 cells; Selank vs GABA vs olanzapine vs combinations; qPCR of 84 GABAergic/neurotransmission genes (Filatova 2017 Front Pharmacol) | Selank alone and with GABA/olanzapine alter expression of GABAergic neurotransmission genes in IMR-32 LITERATURE (PMID 28293190 / DOI 10.3389/fphar.2017.00089 / PMC5328971) — GABA-system gene-expression prior; NOT residual-under-GABA-match H2H |
| Volkova_Selank_GABAergic_gene_expression_in_vivo | LITERATURE | Rat frontal cortex in vivo; Selank vs GABA; qPCR of 84 neurotransmission genes at 1 h and 3 h (Volkova 2016 Front Pharmacol) | Selank and GABA change overlapping GABAergic/neurotransmission gene-expression sets in rat frontal cortex with positive correlation LITERATURE (PMID 26924987 / DOI 10.3389/fphar.2016.00031 / PMC4757669) — GABAergic gene prior; NOT residual-under-GABA-match H2H |
| Kozlovskaya_Selank_tuftsin_adaptive_behavior_stress | LITERATURE | White lab male rats; C57BL/6 and Balb/c mice; Wistar rats; tuftsin-family peptides including Selank; conflict/emotional-stress adaptive behavior panel (Kozlovskaya 2003 Neurosci Behav Physiol) | Selank and tuftsin-family peptides show positive emotional and antistress/adaptive-behavior effects under conflict stress LITERATURE (PMID 14969422 / DOI 10.1023/a:1025988519919) — adaptive-behavior prior; NOT residual-under-GABA-match H2H |
| Medvedeva_Selank_diazepam_UCMS_synergy | LITERATURE | Rats; unpredictable chronic mild stress (UCMS) ± Selank ± diazepam (individual and combined); elevated plus maze anxiety indicators (Medvedeva 2017 Behav Neurol) | Selank enhances diazepam anxiolysis under UCMS; combined Selank+diazepam restores anxiety indicators toward pre-stress values LITERATURE (PMID 28280289 / DOI 10.1155/2017/5091027 / PMC5322660) — BDZ-class synergy / co-admin prior; NOT residual H2H under GABA-A/BDZ match abolish |
| matched_residual_Selank_under_GABA_A_BDZ_match_H2H | UNKNOWN | Same stressor ± Selank ± GABA-A / benzodiazepine-matched condition (e.g. bicuculline, flumazenil, or BDZ-occupancy match) — match titrated to abolish GABA-class anxiolysis, plus anxiolytic / adaptive-behavior endpoint | dedicated residual Selank anxiolytic / adaptive-behavior phenotype under GABA-A / BDZ match that abolishes GABA-class anxiolysis not found (soft-complete Q_resid NON-MATCH / Q_resid_tight=0 / Q_necess NON-MATCH not PARTIAL / Q_necess_b=0 / Q_P20 adjacent NON-MATCH / FOXO4∩Selank=0 / BPC∩Selank review NON-MATCH / N18∩Selank chemistry noise / P15–P19 drift empty/noise) — UNKNOWN + missing_search |
| residual_Selank_anxiolytic_ge50pct_of_Selank_without_GABA_match | PREDICTION | Pre-registered matched stressor ± Selank ± GABA-A / benzodiazepine-matched condition (e.g. bicuculline, flumazenil, or BDZ-occupancy match); GABA-A/BDZ-match condition must abolish GABA-class anxiolysis first, then score residual Selank anxiolytic / adaptive-behavior vs Selank without-GABA-A/BDZ-match arm under matched stressor | under GABA-A / benzodiazepine-matched condition that abolishes GABA-class anxiolysis, residual Selank anxiolytic / adaptive-behavior ≥50% of the Selank without-GABA-A/BDZ-match arm on the same panel (named comparator = Selank without-GABA-A/BDZ-match arm under matched stressor); α/N pre-specified — do not invent observed % / KD / dosing |
| competing_incomplete_GABA_match_or_GABA_class_not_abolished_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual is only incomplete GABA-A/BDZ match, GABA-class anxiolysis not abolished, absent residual to score, or block-QC failure | incomplete-GABA-A/BDZ-match / GABA-class-anxiolysis-not-abolished / no-residual-to-score / block-QC-fail allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove matched stressor ± Selank ± GABA-A / benzodiazepine-matched condition under GABA-A/BDZ-match that first abolishes GABA-class anxiolysis, then scores residual Selank anxiolytic / adaptive-behavior: Without the GABA-A/BDZ-match × residual H2H, separate Filatova GABA gene LITERATURE, Volkova GABAergic gene LITERATURE, Kozlovskaya adaptive-behavior LITERATURE, and Medvedeva Selank×diazepam synergy LITERATURE cannot show gaba-insufficiency of residual Selank under GABA-match abolish.
- remove GABA-A/BDZ-match abolish gate plus Selank without-GABA-A/BDZ-match arm as the named residual comparator (vs Filatova/Volkova gene-alone / Medvedeva synergy-alone / GABA-class attribution-alone): Without the GABA-match abolish gate and Selank without-GABA-match comparator under the same match condition, the card collapses into Filatova/Volkova/Kozlovskaya/Medvedeva phenotype prior or generic GABA-class framing and loses gaba-insufficiency contrast.
- remove P15≠P21 + P16≠P21 + P17≠P21 + P18≠P21 + P19≠P21 + P20≠P21 + N18≠P21 + P1–P20≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, P19 ARA290/IRR, P20 Semax/TrkB, N18 theanine/adenosine, empty PubMed, Filatova/Volkova/Kozlovskaya/Medvedeva alone, or FOXO4/BPC framing as already deciding residual-under-GABA-match would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered matched stressor ± Selank ± GABA-A / benzodiazepine-matched condition (e.g. bicuculline, flumazenil, or BDZ-occupancy match) where GABA-A/BDZ-match abolishes GABA-class anxiolysis, residual Selank anxiolytic / adaptive-behavior is <50% of the Selank without-GABA-A/BDZ-match arm under that same condition — so GABA-class-attribution framing survives and gaba-insufficiency residual fails — when incomplete GABA-A/BDZ match, GABA-class anxiolysis-not-abolished, absent residual, or block-QC artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock one stressor ± Selank ± GABA-A / benzodiazepine-matched condition (e.g. bicuculline, flumazenil, or BDZ-occupancy match) with block QC that abolishes GABA-class anxiolysis, anxiolytic / adaptive-behavior readout, and ≥50%-of-Selank-without-GABA-match residual gate before claiming residual under GABA-match; prefer named published Selank anxiety/adaptive-behavior panel (elevated plus maze / conflict stress) with GABA-A antagonist / BDZ antagonist / BDZ-occupancy match, and Filatova IMR-32 GABAergic gene panel for block-QC support, before new animal/human; do not treat P15 or P16 or P17 or P18 or P19 or P20 or N18 or P1–P20 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO or ARA290/IRR or Semax/TrkB/BDNF or theanine/adenosine/caffeine; no dosing; NOT FOXO4×LOF.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=gaba-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Filatova Selank/GABA gene expression IMR-32; Volkova Selank GABAergic gene expression in vivo; Kozlovskaya Selank tuftsin adaptive behavior stress; Medvedeva Selank×diazepam UCMS synergy; P15 (BPC residual-FBXO22 ≠ Selank×GABA residual; P15 ≠ P21); P16 (LKKTETQ-Cc ≠ Selank×GABA residual; P16 ≠ P21); P17 (MOTS-c/folate ≠ Selank×GABA residual; P17 ≠ P21); P18 (SS-31/ROS ≠ Selank×GABA residual; P18 ≠ P21); P19 (ARA290/IRR ≠ Selank×GABA residual; P19 ≠ P21); P20 (Semax/TrkB ≠ Selank×GABA; Selank≠Semax; GABA≠TrkB; P20 ≠ P21); N18 (theanine/adenosine ≠ Selank×GABA; N18 ≠ P21); P1–P20 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P21.card.md card_sha256: ceed74a9dff61774969a68ac3014bc781dfc739c3e8f418d1dfd48a5f2c9ca5d
Mol Labs public report: PENDING dual-publish